Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2015 Nov 24

PMID 26593949

Citations 41

Authors

Diane Ojo

Xiaozeng Lin

Nicholas Wong

Yan Gu

Damu Tang

Affiliations

Soon will be listed here.

Abstract

Androgen deprivation therapy (ADT) has been the standard care for patients with advanced prostate cancer (PC) since the 1940s. Although ADT shows clear benefits for many patients, castration-resistant prostate cancer (CRPC) inevitably occurs. In fact, with the two recent FDA-approved second-generation anti-androgens abiraterone and enzalutamide, resistance develops rapidly in patients with CRPC, despite their initial effectiveness. The lack of effective therapeutic solutions towards CRPC largely reflects our limited understanding of the underlying mechanisms responsible for CRPC development. While persistent androgen receptor (AR) signaling under castration levels of serum testosterone (<50 ng/mL) contributes to resistance to ADT, it is also clear that CRPC evolves via complex mechanisms. Nevertheless, the physiological impact of individual mechanisms and whether these mechanisms function in a cohesive manner in promoting CRPC are elusive. In spite of these uncertainties, emerging evidence supports a critical role of prostate cancer stem-like cells (PCSLCs) in stimulating CRPC evolution and resistance to abiraterone and enzalutamide. In this review, we will discuss the recent evidence supporting the involvement of PCSLC in CRPC acquisition as well as the pathways and factors contributing to PCSLC expansion in response to ADT.

Citing Articles

Iroquois homeobox 4 (IRX4) derived micropeptide promotes prostate cancer progression and chemoresistance through Wnt signalling dysregulation.

Fernando A, Liyanage C, Srinivasan S, Panchadsaram J, Rothnagel J, Clements J Commun Med (Lond). 2024; 4(1):224.

PMID: 39487222 PMC: 11530646. DOI: 10.1038/s43856-024-00613-9.

Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment.

Miller C, Likasitwatanakul P, Toye E, Hwang J, Antonarakis E Expert Rev Anticancer Ther. 2024; 24(11):1085-1100.

PMID: 39275993 PMC: 11499039. DOI: 10.1080/14737140.2024.2405103.

Advances in antitumour therapy with oncolytic herpes simplex virus combinations.

Qi X Discov Oncol. 2024; 15(1):302.

PMID: 39046631 PMC: 11269532. DOI: 10.1007/s12672-024-01165-z.

Systematic review and integrated analysis of prognostic gene signatures for prostate cancer patients.

An Y, Lu W, Li S, Lu X, Zhang Y, Han D Discov Oncol. 2023; 14(1):234.

PMID: 38112859 PMC: 10730790. DOI: 10.1007/s12672-023-00847-4.

State-of-the-art therapeutic strategies for targeting cancer stem cells in prostate cancer.

Ramesh S, Selvakumar P, Ameer M, Lian S, Abdullah Alzarooni A, Ojha S Front Oncol. 2023; 13:1059441.

PMID: 36969009 PMC: 10035756. DOI: 10.3389/fonc.2023.1059441.

References

Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J . Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009; 138(2):245-56. PMC: 2726827. DOI: 10.1016/j.cell.2009.04.056. View

Li Y, Chan S, Brand L, Hwang T, Silverstein K, Dehm S . Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2012; 73(2):483-9. PMC: 3549016. DOI: 10.1158/0008-5472.CAN-12-3630. View

Yokoyama N, Shao S, Hoang B, Mercola D, Zi X . Wnt signaling in castration-resistant prostate cancer: implications for therapy. Am J Clin Exp Urol. 2014; 2(1):27-44. PMC: 4219296. View

Salem M, Garcia J . Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer. Curr Oncol Rep. 2011; 13(2):92-6. DOI: 10.1007/s11912-011-0153-4. View

Berger M, Lawrence M, Demichelis F, Drier Y, Cibulskis K, Sivachenko A . The genomic complexity of primary human prostate cancer. Nature. 2011; 470(7333):214-20. PMC: 3075885. DOI: 10.1038/nature09744. View

Akimoto S, Okumura A, Fuse H . Relationship between serum levels of interleukin-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients. Endocr J. 1998; 45(2):183-9. DOI: 10.1507/endocrj.45.183. View

Vlashi E, Pajonk F . Cancer stem cells, cancer cell plasticity and radiation therapy. Semin Cancer Biol. 2014; 31:28-35. PMC: 4291301. DOI: 10.1016/j.semcancer.2014.07.001. View

Blanpain C, Fuchs E . Stem cell plasticity. Plasticity of epithelial stem cells in tissue regeneration. Science. 2014; 344(6189):1242281. PMC: 4523269. DOI: 10.1126/science.1242281. View

Nouri M, Ratther E, Stylianou N, Nelson C, Hollier B, Williams E . Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention. Front Oncol. 2015; 4:370. PMC: 4274903. DOI: 10.3389/fonc.2014.00370. View

10.

Germann M, Wetterwald A, Guzman-Ramirez N, van der Pluijm G, Culig Z, Cecchini M . Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. Stem Cells. 2012; 30(6):1076-86. DOI: 10.1002/stem.1087. View

11.

Domingo-Domenech J, Vidal S, Rodriguez-Bravo V, Castillo-Martin M, Quinn S, Rodriguez-Barrueco R . Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell. 2012; 22(3):373-88. PMC: 5989708. DOI: 10.1016/j.ccr.2012.07.016. View

12.

Robinson J, Hickey T, Warren A, Vowler S, Carroll T, Lamb A . Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype. Oncogene. 2013; 33(50):5666-74. PMC: 4051595. DOI: 10.1038/onc.2013.508. View

13.

Tannock I, de Wit R, Berry W, Horti J, Pluzanska A, Chi K . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351(15):1502-12. DOI: 10.1056/NEJMoa040720. View

14.

Mulholland D, Tran L, Li Y, Cai H, Morim A, Wang S . Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell. 2011; 19(6):792-804. PMC: 3157296. DOI: 10.1016/j.ccr.2011.05.006. View

15.

Kregel S, Szmulewitz R, Vander Griend D . The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells. Prostate. 2014; 74(15):1530-43. PMC: 4174985. DOI: 10.1002/pros.22870. View

16.

Yi H, Cho H, Cho S, Jo K, Park J, Kim N . Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells. Int J Oncol. 2012; 41(1):310-6. DOI: 10.3892/ijo.2012.1447. View

17.

Berthold D, Pond G, Soban F, de Wit R, Eisenberger M, Tannock I . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008; 26(2):242-5. DOI: 10.1200/JCO.2007.12.4008. View

18.

Masai M, Sumiya H, Akimoto S, Yatani R, Chang C, Liao S . Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates. Prostate. 1990; 17(4):293-300. DOI: 10.1002/pros.2990170405. View

19.

Boman B, Fields J . An APC:WNT Counter-Current-Like Mechanism Regulates Cell Division Along the Human Colonic Crypt Axis: A Mechanism That Explains How APC Mutations Induce Proliferative Abnormalities That Drive Colon Cancer Development. Front Oncol. 2013; 3:244. PMC: 3819610. DOI: 10.3389/fonc.2013.00244. View

20.

Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G . Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009; 15(5):559-65. PMC: 2839160. DOI: 10.1038/nm.1944. View